insights_auto
Why is CVM up ၂၉.၆၉%?
Dive Deeperchevron_right
CVM:NYSEAMERICAN
CEL-SCI Corp
၁.၆၆ US$
arrow_upward
+၂၉.၆၉%(+၀.၃၈) 1D
၁.၆၇ US$
arrow_upward
+၀.၆၀% (+၀.၀၁၀၀)bedtimeAfter hours
Closed: နို ၁၆, GMT-၅ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CVM...
Open
၁.၃၂ US$
High
၁.၇၅ US$
Low
၁.၃၀ US$
Mkt. cap
၂.၉၂ ကုဋေ
Avg. vol.
၁.၉၀ သိန်း
Volume
၁.၁၇ သန်း
52-wk high
၇.၈၀ US$
52-wk low
၀.၈၉ US$
EPS
-၂.၆၈ US$
Beta
၀.၆၂
Shares outstanding
၁.၇၆ ကုဋေ
No. of employees
၄၃
Open
၁.၃၂ US$
High
၁.၇၅ US$
Low
၁.၃၀ US$
Mkt. cap
၂.၉၂ ကုဋေ
Avg. vol.
၁.၉၀ သိန်း
Volume
၁.၁၇ သန်း
52-wk high
၇.၈၀ US$
52-wk low
၀.၈၉ US$
EPS
-၂.၆၈ US$
Beta
၀.၆၂
Shares outstanding
၁.၇၆ ကုဋေ
No. of employees
၄၃
News stories
From web sources and news partners
TradingView
·
ပြီးခဲ့သည့် ၁ နာရီ
Dow, S&P 500, Nasdaq Futures Mixed Ahead Of Much-Anticipated Nvidia Earnings, Anthropic IPO: SLS, BABA, JPM, OMER In Focus
ChartMill
·
ပြီးခဲ့သည့် ၉ နာရီ
S&P 500 Top Movers: Gainers and Losers for Nov. 16, 2026
The Motley Fool
·
ပြီးခဲ့သည့် ၁၄ နာရီ
Is an Equal-Weight S&P 500 Fund Safer Right Now Than the One You Own?
Traders Union
·
ပြီးခဲ့သည့် ၆ နာရီ
Michael A. Gayed: S&P 500 fell 19.35% and high yield dropped 5.9% in Q4 2018 selloff
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees၄၃
Foundedမတ် ၁၉၈၃
Headquartersဗီယင်နာ, ဗာဂျီးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Websitecel-sci.com